Comparative study of a mutant tissue-type plasminogen activator, YM866, with a tissue-type plasminogen activator in a canine model of femoral arterial thrombosis.

doi:10.1111/j.2042-7158.1996.tb05897.x

Back to search

Article

Comparative study of a mutant tissue-type plasminogen activator, YM866, with a tissue-type plasminogen activator in a canine model of femoral arterial thrombosis.

The Journal of pharmacy and pharmacology - 1 Oct 1996

Kawasaki T, Kaku S, Sakai Y, Takenaka T

Abstract excerpt

Because tissue-type plasminogen activator (tPA), used to treat myocardial infarction, has several disadvantages thought to be connected with its low half-life, mutants of tPA have been prepared with longer half-lives. We have compared the thrombolytic effect of such a mutant, YM866, with that of...

Topics

Animals
Blood Coagulation
Dogs
Female
Femoral Artery
Fibrinolytic Agents
Male
Mutation
Recombinant Proteins
Regional Blood Flow
Thrombosis
Tissue Plasminogen Activator

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.